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ABSTRACT 
Depression is the second leading cause of disability worldwide, and is associated with 
substantial functional impairment and poor health implications in older adults. These adverse 
outcomes are exacerbated in older adults who exhibit comorbid depression and cerebrovascular 
burden (CVB). Given that the population of older adults is projected to double by year 2050, a 
process model of the development of depression in later-life and a subsequent clear delineation 
of the relationship between CVB and depression is paramount. One explanation of this process 
of disease development is the vascular depression theory, however alternative hypotheses have 
not been exhaustively falsified and the literature consists of methodological barriers that produce 
potentially unreliable results. The goals of this thesis are (1) to examine the interrelationship 
between CVB and depressive symptomatology from mid-life to later-life, and (2) to assess a 
potential genetic modifier of the CVB/depressive symptomatology relationship. Participants 
were drawn from the Wisconsin Longitudinal Study, which represents the 1957 graduating class 
from Wisconsin high schools. Data was drawn from three waves (1993, 2004, and 2011), 
spanning 18 years. Study 1 utilized a dual-change model to evaluate the relationship between 
CVB and depressive symptomatology from mid-life to later-life. Results indicated that 
depressive symptomatology at both follow-up waves was predicted by earlier depressive 
symptomatology. Prior CVB significantly predicted future depressive symptomatology in both 
2004 and 2011. Depressive symptomatology in 2004 significantly predicted CVB in 2011. Thus, 
CVB significantly predicted future depressive symptomatology even after accounting for prior 
depressive symptomatology. Study 2 utilized a repeated-measures ANOVA and a moderated 
path structural model to evaluate the moderating effect of ApoE carriage on the relationship 
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between CVB and depressive symptomatology. Results indicated that ApoE carriage has no 
significant main effect on depressive symptomatology, nor is it a significant moderator of the 
relationship between CVB and depressive symptomatology. Overall findings strongly support 
the vascular depression theory, and do not implicate ApoE carriage in the manifestation of 
depressive symptomatology. Future research should longitudinally evaluate the relationship 
between CVB and depressive symptomatology across a greater number of defined time points 
and with a more diverse sample. Lastly, future research should continue to identify genetic risk 
factors that influence the development of detrimental disease processes.  
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CHAPTER 1: INTRODUCTION 
Depression is the second leading cause of disability worldwide, and is associated with 
significant functional impairment and poor health implications in older adults (Bruce, Seeman, 
Merrill, & Blazer, 1994; Ferrari et al., 2013; Lichtenberg, Gibbons, Nanna, & Blumenthal, 
1993). When combined with comorbid cerebrovascular burden (CVB), the detrimental effects of 
depression in later-life are exacerbated (Yochim, Mast, & Lichtenberg, 2003). The number of 
adults over the age of 65 in the United States is projected to double by year 2050, comprising 
20% of the total U.S. population. This imminent increase in the proportion of older adults 
prioritizes the pursuit to effectively predict, prevent, and treat detrimental disease processes (i.e., 
comorbid CVB and depression).  
Past efforts to conceptualize the development of depressive symptomatology in later-life 
have generated the vascular depression theory, whereby vascular disease may “predispose, 
precipitate, or perpetuate” depressive symptoms among older adults (Alexopoulos et al., 1997, p. 
915). Vascular depression theory posits a temporal sequence of disease development such that 
depressive symptomatology develops as a consequence of CVB, however two contrary 
hypotheses are evident in the literature. First, depression is episodic in nature, with past 
depression being among the strongest predictors of future depression (Djernes, 2006; Lewinsohn, 
Zeiss, & Duncan, 1989). Second, a review of the health psychology literature broadly concludes 
depression as the antecedent to a subsequent increase in vascular load, suggesting a directly 
opposite system of comorbid CVB and depressive symptomatology development to that 
proposed in the vascular depression theory. Without adequate examination of these alternative 
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hypotheses, CVB cannot be conclusively identified as the catalyst of increased depressive 
symptomatology in later-life. 
A second avenue through which researchers are attempting to delineate the development 
of depressive symptomatology in later-life is through the identification of neurobiological 
correlates. One meta-analysis identified apolipoprotein E (ApoE) as one of the most strongly 
associated genes with major depressive disorder (MDD; Lopez-Leon et al., 2008). ApoE is most 
prominently recognized as a determinant in the development of Alzheimer’s disease (AD), 
however it has also been implicated in the manifestation of Parkinson’s disease and Wilson’s 
disease (Li et al., 2004; Liu, Kanekiyo, Xu, & Bu, 2013; Schiefermeier et al., 2000). Specifically, 
the presence of the ApoE-4 allele has been related to detrimental health outcomes, such as 
greater risk of developing, and lower age of onset for, certain neurodegenerative diseases 
(Blacker et al., 1997; Farrer et al., 1997; Li et al., 2004; Schiefermeier et al., 2000). Given the 
neurobiological correlates of disordered mood and CVB, it is logical to assume a similar effect of 
ApoE carriage on the development of depressive symptomatology, whether it is a direct effect on 
the development of depressive symptoms or a moderating effect on the relationship between 
CVB and depressive symptomatology. However, a review of the literature reflects inconsistent 
findings, such that some studies show a detrimental effect of ApoE-4 on depressive 
symptomatology (Butters et al., 2003; Rigaud et al., 2001; Skoog et al., 2015), while other 
studies show no association between the two constructs (Cervilla, Prince, Joels, Russ, & 
Lovestone, 2004; Surtees et al., 2009). 
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Goals of this thesis are to examine the relationship between CVB and depressive 
symptomatology from mid-life to later-life (Study 1), and to examine whether ApoE carriage 
moderates the effect that CVB has on the development of depressive symptomatology (Study 2). 
The present thesis addresses common methodological barriers (i.e., small sample sizes and 
samples that are too young for an apparent relationship, listwise deletion of participants with 
missing data, and cross-sectional designs) to most effectively evaluate the relationships between 
CVB, depressive symptomatology, and ApoE. Results of this thesis may improve our 
understanding of interrelated disease processes, thus informing integrated healthcare delivery.  
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CHAPTER 2: THE IMPACT OF CEREBROVASCULAR BURDEN ON 
DEPRESSIVE SYMPTOMATOLOGY FROM ADULTHOOD TO LATER-
LIFE 
Introduction 
The number of adults over the age of 65 in the United States is projected to reach an 
estimated 88.5 million by year 2050, and will constitute 20% of the total United States 
population (Shrestha & Heisler, 2011). Depression is a common and multi-faceted late-life 
comorbidity in this growing population, and one that imposes significant functional impairment 
and physical health implications among older adults (Bruce et al., 1994; Lichtenberg et al., 1993; 
Yochim et al., 2003).  Past efforts to conceptualize the phenomenon of late-life depression, 
particularly late-onset depression, have yielded the vascular depression theory.  Alternate 
perspectives from the epidemiological and health psychology literatures call into question some 
core assumptions of the vascular depression theory.  To our knowledge, those competing 
perspectives have not been directly contrasted using longitudinal data.  
The empirical perspective reflects a consistent finding that depression has a chronic and 
recurrent trajectory, with past depression being among the strongest predictors of future 
depression (Djernes, 2006).  For instance, past work has found that the probability of the 
recurrence of depressive episodes is positively associated with the number of previous episodes 
(Lewinsohn et al., 1989). Vascular depression theory, however, posits a temporal sequence such 
that depressive symptomatology emerges in later-life only after the development of significant 
cerebrovascular burden (CVB; Alexopoulos et al., 1997). The trajectory posited by vascular 
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depression theory neglects the influence of prior episodes of depression, and thus may confound 
the effects of earlier CVB with prior depressive symptomatology.  
The second alternative perspective to the vascular depression hypothesis is based on the 
health psychology literature, and posits that depression has not only been identified as a 
consequence of disordered health; a review of the health psychology literature broadly concludes 
that depression is an antecedent to subsequent increases in vascular load, suggesting a hypothesis 
that is directly contrary to vascular depression theory. For instance, depressed mood is positively 
associated with medical noncompliance (Carney, Freedland, Eisen, Rich, & Jaffe, 1995; Glazer, 
Emery, Frid, & Banyasz, 2002; Wang et al., 2002). In turn, substandard medical regimen 
compliance engenders poor health outcomes, particularly for people with chronic comorbidities 
that affect the brain such as hypertension, various heart problems, and diabetes. Depressed 
individuals are more likely to smoke and to have ever smoked compared to their non-depressed 
counterparts (Covey, Glassman, & Stetner, 1998; Glassman et al., 1990). Longitudinally, 
depression has been consistently indicated as a predictor of CVB, as demonstrated with the 
development of hypertension at 5-year follow-up (Davidson, Jonas, Dixon, & Markovitz, 2000), 
the diagnosis of coronary heart disease during a 7-year study (Nabi et al., 2010), and incident 
acute myocardial infarction and mortality in a 27-year follow-up (Barefoot & Schroll, 1996). 
Depression has also been shown to increase an individual’s vulnerability to the onset of type 2 
diabetes (Knol et al., 2006) as well as incident hypertension (Jonas, Franks, & Ingram, 1997). 
Therefore, it may be premature to assume that CVB is the antecedent in the hypothesized CVB-
depression relationship. 
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Extant research has not examined how high CVB in mid-life predicts depressive 
symptomatology in later life over and above mid-life depressive symptomatology. Nor has past 
vascular depression research examined the competing and seemingly contradictory hypothesis 
(i.e., depression as the antecedent to CVB). The present study is an attempt to elucidate this 
apparent conflict by utilizing longitudinal data and a three-faceted hypothesis. Specifically, the 
longitudinal inter-relationships between CVB and depression will be examined across three 
waves spanning mid-life (age 53.20 years) to later-life (age 71.21 years). The temporal sequence 
between depressive symptomatology and the manifestation of CVB among aging adults will be 
examined using a dual change model.  This model tests the hypotheses that (1) mid-life 
depressive symptomatology will predict later-life depressive symptomatology, and that (2) CVB 
in mid-life will positively predict future depressive symptomology even after controlling for past 
depressive symptomatology, as posited by the vascular depression theory (Alexopoulos et al., 
1997). The inverse hypothesis suggested by Barefoot and Schroll (1996), Nabi et al. (2010), and 
Davidson et al. (2000), that (3) mid-life depressive symptomatology will predict later-life CVB, 
is also examined by this model.  This dual change model will include both A) autoregressive 
pathways reflecting the hypothesized relationship between past CVB on future CVB and past 
depressive symptomatology on future depressive symptomatology, respectively; and B) cross-
lagged pathways reflecting the hypothesized effect of past CVB on future depressive 
symptomatology and of past depressive symptomatology on future CVB, respectively (see 
examined model in Figure 2.1).  Based on past work, sex, education, and income were selected a 
priori as control variables.  
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Method 
Participants 
 The present study will utilize data collected through the Wisconsin Longitudinal Study 
(WLS). The WLS is a longitudinal cohort study that includes over 10,000 randomly selected 
representatives of the 1957 high school graduating class from Wisconsin. Participants were 
originally recruited in 1957 with an in-person questionnaire, then follow up data collections were 
gathered in 1964 (mail survey of parents), 1975 (telephone survey), 1993 (telephone and mail 
surveys), 2004 (telephone and mail surveys), and 2011 (in-person survey and mail survey; Herd, 
Carr, & Roan, 2014). The WLS includes a wide breadth of information on its participants, 
including demographics, mental health status, medical health status, genetic variables, and 
measures of cognition. The initial goals of the WLS were to assess the demand for post-high 
school education, to determine if promising high school students were attending college or 
university, and what circumstances contributed to these education plans via a state-sponsored 
questionnaire (Little, 1958). Follow up studies were originally conducted to examine the extent 
to which family background and childhood experiences and aspirations affected educational and 
occupational attainment (Herd et al., 2014). Since 1991, the WLS has been principally funded by 
the National Institutes for Health and National Institute on Aging, with additional support 
provided by the Vilas Estate Trust, the National Science Foundation, the Spencer Foundation, 
and the Graduate School of the University of Wisconsin-Madison (Herd et al., 2014).  
 The data relevant to this study is found in the 1993, 2004, and 2011 data collection 
waves. Participants who have missing data within the variables of interest were excluded from 
the study. 
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Measures 
Demographic Variables. Age, sex, and income were self-reported by the participant. 
Education was assessed as self-reported years of formal schooling.  
Cerebrovascular Health Variables. All medical variables used in this study were 
collected by self-report. Participants were asked “Has a doctor ever told you that you have . . .” 
high blood pressure or hypertension; high blood sugar; diabetes; heart attack, coronary heart 
disease, angina, congestive heart failure, or other heart problems; stroke. In this study, these 
comorbidities were grouped into three categories by organ system. Presence of hypertension was 
identified by endorsement of high blood pressure or hypertension. Presence of blood sugar 
dysregulation was identified by endorsement of high blood sugar or diabetes. Presence of cardiac 
disease was identified by endorsement of heart attack, coronary heart disease, angina, congestive 
heart failure, or other heart problems. Participants endorsing a history of stroke were excluded, 
as these individuals have been shown to be more likely to experience subsequent mood 
dysregulation (Bour et al., 2009). 
Total CVB. Total CVB is a continuous measure of cerebrovascular risk factors, 
comprising a participant’s scores on the hypertension, high blood sugar/diabetes, and heart 
disease measures and emitting a total score ranging from 0-3.  
Outcome Variable 
 Depression. Depression was measured using the Center for Epidemiological Studies 
Depression (CES-D) measure (L.S. Radloff, 1977). The CES-D collapses ranges of scores (0, 1-
2, 3-4, and 5-7, then recodes these ranges to 0, 1, 2, or 3), for an individual’s total score ranging 
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from 0-60. The internal consistency of the CES-D is high for older adults (coefficient alpha .85 
to .90), as is the validity of the measure (Lenore S. Radloff & Teri, 1986). Although the CES-D 
has a suggested cutoff score for probable depression, the present study will utilize this measure 
as a continuous degree of depressive symptomatology. 
Statistical Methods 
A dual-change model was employed to represent the relationship between CVB and 
depressive symptomatology across three time points ranging from mid-life (year 1993, mean age 
53.20 years) to later-life (year 2011, mean age 71.21 years; see Figure 2.1). This model includes 
autoregressive pathways modeling to demonstrate, for example, the effect of CVB at time 1 on 
CVB at time 2. This model also includes cross-lagged pathways representing the hypothesized 
causal effect of CVB on depressive symptomatology, and vice-versa, over time. Full information 
maximum likelihood estimation (FIML) was utilized to prevent listwise deletion and, in turn, to 
prevent the underrepresentation of at-risk respondents on variables associated with mortality-
based attrition (e.g., those who are socially marginalized which may affect one’s access to 
healthcare, or those carrying greater medical burden). Data was prepared in SPSS and the 
structural equation model analysis was performed utilizing Mplus software program (Muthen & 
Muthen, 2012). 
Results 
 The final sample consisted of 5,175 participants. Participant characteristics are provided 
in Table 1.1.  Mean age of participants was 53 years in 1993, 64 years in 2004, and 71 years in 
2011. The largest proportion of the sample that was estimated using FIML was for depressive 
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symptomatology; 19.1%, 17.3%, and 23.5% of participants’ depressive symptomatology data 
was estimated in 1993, 2004, and 2011, respectively. Participant CVB data was estimated less 
frequently, with 12.8%, 0.004%, and 0.006% of participant’s CVB data estimated in 1993, 2004, 
and 2011, respectively.  
The temporal sequence between depressive symptomatology and the manifestation of 
CVB among aging adults was examined using a dual-change model, incorporating three waves 
of data (1993, 2004, and 2011; Figure 2.1). Overall, results suggest that the hypothesized model 
fit the data very well (RMSEA=0.047; Comparative Fit Index (CFI)=0.963, χ2(57, 
N=5175)=8573.411, p<.00005). With respect to the model’s autoregressive pathways evaluating the 
relationship demonstrating how previous CVB effects future CVB, greater CVB in 1993 
significantly predicted CVB in 2004 (β=0.492, SE=0.011, p<.001). Further, greater CVB in 2004 
was significantly associated with greater CVB in 2011 (β=0.699, SE=0.007, p<.001). The 
autoregressive pathways demonstrating the relationship between prior and future depressive 
symptomatology revealed a similar relationship, whereby higher CES-D scores in 1993 were 
significantly associated with higher CES-D scores in 2004 (β=0.546, SE=0.011, p<.001), and 
higher CES-D scores in 2004 were significantly related to higher CES-D scores in 2011 
(β=0.603, SE=0.011, p<.001). With respect to the cross-lagged pathways identifying the 
relationship between CVB and depressive symptomatology from previous waves to future 
waves, greater CVB in 1993 was significantly associated with higher CES-D scores in 2004 
(β=0.038, SE=0.013, p=.004). Greater CVB in 2004 was also associated with higher CES-D 
scores in 2011 (β=0.027, SE=0.013, p=.042). Conversely, an effect of past CES-D scores on 
level of CVB at future waves was only evident in the last wave; higher CES-D scores in 2004 
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were significantly positively predictive of level of CVB in 2011 (β=0.022, SE=0.011, p=.038). 
Overall, the model accounted for 38.2% of the variance in depressive symptomatology in 2011. 
To assess the pathway by which CVB in 1993 significantly predicts depressive 
symptomatology in 2011, two indirect pathways were analyzed in the model: (1) CVB in 1993 to 
depressive symptomatology in 2011 by way of CVB in 2004, and (2) CVB in 1993 to depressive 
symptomatology in 2011 by way of depressive symptomatology in 2004. Both indirect pathways 
were statistically significant, whereby CVB in 1993 significantly predicted depressive 
symptomatology in 2011 through CVB in 2004 (β=0.013, SE=0.007, p=.042) and CVB in 1993 
significantly predicted depressive symptomatology in 2011 through depressive symptomatology 
in 2004 (β=0.023, SE=0.008, p=.004). 
 In addition to the primary variables of interest, all control variables used in the model had 
statistically significant pathways dependent upon the wave. Specifically, level of education was 
significantly inversely related to the level of CVB in 1993 (β=-0.064, SE=0.015, p<.001), 2004 
(β=-0.064, SE=0.013, p<.001), and 2011 (β=-0.042, SE=0.010, p<.001). Level of education was 
also significantly inversely related to depressive symptomatology in 2004 (β=-0.029, SE=0.013, 
p=.031) and 2011 (β=-0.042, SE=0.013, p=.002). Participant income was significantly inversely 
associated with level of depressive symptomatology in 1993 (β=-0.120, SE=0.016, p<.001), 
2004, (β=-0.036, SE=0.014, p=.010), and 2011 (β=-0.051, SE=0.014, p<.001). Sex of the 
participant was significantly associated with level of CVB in 1993 (β=-0.059, SE=0.015, 
p<.001), 2004 (β=-0.088, SE=0.013, p<.001), and 2011 (β=-0.068, SE=0.010, p<.001), 
suggesting that male sex is associated with higher levels of CVB. Lastly, sex of the participant 
was significantly associated with depressive symptomatology in 1993 (β=0.082, SE=0.015, 
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p<.001) and in 2004 (β=0.039, SE=0.013, p=.004), whereby female sex was associated with 
higher depressive symptomatology.  
Discussion 
Results support hypothesis 1 based on the epidemiological depression literature that past 
depressive symptomatology was a consistent predictor of future depressive symptomatology.  
Results also supported hypothesis 2 based on the vascular depression hypothesis that even after 
controlling for the effects of past depressive symptomatology, high CVB still predicted greater 
endorsement of depressive symptomatology later in life.  Findings partially supported hypothesis 
3 based on the health psychology literature that mid-life depressive symptomatology would 
predict later-life depressive symptomatology. 
These findings address an unexamined assumption of the vascular depression theory. Past 
depression has been identified as one of the strongest predictors of future depression (Djernes, 
2006; Lewinsohn et al., 1989), however the vascular depression theory assumes a temporal 
sequence that indicates CVB as the predecessor and catalyst to a subsequent increase in 
depressive symptomatology. Results of this study strongly support the vascular depression theory 
by indicating mid-life CVB as a significant risk factor for the development of depressive 
symptomatology in later-life above and beyond that associated with depressive symptomatology 
earlier in life.  
The vascular depression theory focuses primarily on the unidirectional relationship 
between CVB and depressive symptomatology, a relationship for which the current results 
support. The inverse hypothesis, whereby greater depressive symptomatology at mid-life is 
significantly predictive of CVB in later-life, was partially supported in this study. Higher levels 
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of depressive symptomatology in 2004 were significantly related to increased CVB in 2011; this 
relationship was not evident from 1993 to 2004. This finding corroborates other results 
suggesting that depressive symptomatology is associated with subsequent development of 
cerebrovascular risk factors such as hypertension, diabetes, and heart disease (Barefoot & 
Schroll, 1996; Davidson et al., 2000; Knol et al., 2006; Nabi et al., 2010). This finding highlights 
the need for regular depression screening to allow for the identification of risk factors of, and the 
implementation of preventative measures for, cerebrovascular disease. Primary care clinics, 
where mental health screening and behavioral health specialists are becoming increasingly 
common, are one key setting where such interventions may be employed. 
The twin indirect effects reflect the hypothesized effect through which CVB predisposes 
the development of depressive symptomatology; however, the rate at which CVB in mid-life 
precipitates the development of that depressive symptomatology is heterogeneous in its 
manifestation. The current results implicate this heterogeneity by reflecting multiple measured 
relationships leading to development of depressive symptomatology. One pathway indicated that 
CVB in mid-life (1993) precipitated the development of depressive symptomatology earlier 
(measured in 2004) in the observed 18-year span; this depressive symptomatology perpetuated 
throughout the observed epoch. A second pathway evidenced CVB in mid-life that was 
maintained or intensified during the observed 18-year span, from which depressive 
symptomatology was precipitated and perpetuated at a later time in the epoch (at the 2011 wave) 
compared to the first indirect effect. Given that the current model includes auto-regressive and 
cross-lagged pathways among three time points and two outcome variables (i.e., CVB and 
depressive symptomatology in 1993, 2004, and 2011), the two aforementioned indirect effects 
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were the only ones available to be tested. It is likely that these two measured trajectories reflect 
the variable manifestation of vascular depression symptom development. Future research should 
examine potential modifiers of which the rate of development of depressive symptomatology due 
to CVB is a function. 
 The primary limitation of this study is the use of a racially homogeneous (Caucasian), 
well-educated sample. Future research should seek to replicate these findings with a more 
racially and socioeconomically diverse sample.  A second limitation of this analysis is the use of 
self-reported health data in creating the CVB variable. However, this practice is consistent with 
past research on clinically defined vascular depression. Further, subjective accounts of medical 
burden have yielded high concordance with objective measures (e.g., medical records and 
examinations; Bush, Miller, Golden, & Hale, 1989; Psaty et al., 1995). A third limitation exists 
in the assessment of chronological change that is imposed by using only three defined time 
points over a long span of time (i.e., 18 years). To our knowledge, however, very few datasets 
exist that represent such a large number of participants from mid-life to later-life.  Thus, 
feasibility of a more thorough analysis of these inter-relationships remains limited. 
The findings of this study provide empirical evidence to address an assumption made by 
the vascular depression theory that, to our knowledge, has not been adequately evaluated. A 
primary question raised by these results is whether treatment of mid- to later-life depression can 
prevent the development of chronic cerebrovascular comorbidities such as diabetes, 
hypertension, and heart problems among aging adults. With the predicted significant increase in 
the proportion of older adults over the upcoming decades, the need to identify risk factors for 
disordered health in this aging population is paramount. By implementing preventative 
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interventions for depression in at-risk populations (i.e., individuals with high levels of CVB) 
earlier in the life span, it may reduce the prevalence of associated detrimental health outcomes 
and healthcare utilization. 
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CHAPTER 3: THE IMPACT OF APOE ON THE PREDISPOSITION AND 
PERPETUATION OF THE VASCULAR DEPRESSION EFFECT 
Introduction 
 Depression in later-life is commonly undetected, despite its recognition as the second 
leading cause of disability worldwide, associated substantial functional impairment, and ominous 
physical health implications (Bruce et al., 1994; Ferrari et al., 2013; Lichtenberg et al., 1993). In 
conjunction with comorbid cerebrovascular burden (CVB), the effects of depression in later-life 
are exacerbated (Yochim et al., 2003). Currently the population of adults in the United States 
over the age of 65 years surpasses 44 million (U.S. Census Bureau Population Division, 2014). 
This number is projected to increase over the upcoming decades, reaching an estimated 88.5 
million people by year 2050 and comprising 20% of the total U.S. population (Shrestha & 
Heisler, 2011). This surge in the population of older adults has led to a subsequent increase in 
scrutiny on the most effective way to predict, prevent, and treat detrimental disease processes. 
One avenue by which researchers are examining how best to provide healthcare to older adults is 
through the use of genetic sequencing, which has become more affordable in recent years. A 
strong emphasis has been placed on relating genetic diatheses with environmental and behavioral 
stressors on the development of life-limiting syndromes, allowing for individualized medicine 
which is more efficient, economical, and effective in the prevention and treatment of disease 
(Cortese, 2007). 
 In the movement toward identifying neurobiological correlates to physical and behavior 
disorders, one meta-analysis identified apolipoprotein E (ApoE) as one of the most strongly 
associated genes in terms of the odds ratio for adverse later-life health outcomes, including major 
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depressive disorder (MDD; Lopez-Leon et al., 2008). ApoE was first recognized for its 
implications in lipoprotein metabolism and cardiovascular disease, and has since become 
recognized for its role in cognitive function, immunoregulation, and the manifestation of 
Alzheimer’s disease (AD; Mahley & Huang, 1999). ApoE is a polymorphic protein arising from 
three alleles: e2, e3, and e4; thus, there are six possible combinations of ApoE carriage that, 
when displayed on a continuum, reflect a dimension of ApoE-conferred risk. Allelic frequencies 
of ApoE in Caucasian samples are approximately 7% e2, 77% e3, and 16% e4, with 
corresponding genotypic frequencies of 0.5% e2/e2, 11% e2/e3, 59% e3/e3, 2% e2/e4, 25% 
e3/e4, and 3% e4/e4 (Corder, Lannfelt, Bogdanovic, Fratiglioni, & Mori, 1998). Each allele 
combination implies varying substantial functional consequences. A broad review of the 
literature indicates e3 as most common in frequency and concomitant to normal functioning, 
whereas e2 and e4 are scarcer and have varying functional implications (Mahley & Huang, 
1999). 
 ApoE is more prominently recognized in its relation to the development of AD. Extant 
research suggests a dose-dependent effect of ApoE isoforms on amyloid beta peptide clearance, 
aggregation, and deposition (Liu et al., 2013). When comparing across isoforms, the presence of 
an ApoE-4 allele puts individuals at significantly higher risk for developing AD (for e2/e4, OR = 
2.6; for e3/e4, OR = 3.2; for e4/e4, OR = 14.9; Farrer et al., 1997). The presence of ApoE-4 has 
also been linked to an earlier onset of AD, such that individuals with the e4/e4 genotype have 
been shown to have a mean age of AD onset of 66.4 years compared to all other ApoE 
configurations, who show an average AD onset of 71.3 to 73.6 years (Blacker et al., 1997). 
Similar effects of ApoE-4 on hastened disease development have been indicated in Parkinson’s 
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disease and in Wilson’s disease (Li et al., 2004; Schiefermeier et al., 2000). By contrast, e2 has 
been shown to have a protective effect; in one study, individuals with genotypes e2/e2 and e2/e3 
showed a 40% risk reduction in the development of AD (Farrer et al., 1997). This protective 
effect of ApoE on the development of AD was corroborated by Corder and colleagues (1994), 
whereby AD risk was lowest in individuals with the e2/e3 genotype. Further, 23% of AD cases 
in this meta-analysis were considered “attributable to the absence of an ApoE-2 allele” (Corder 
et al., 1994, p. 180).  
Given that ApoE impacts the manifestation of various neurological diseases, it is logical 
to presume a similar effect exists by which ApoE carriage would affect the pathophysiology of 
depression in later-life. Concurrent with this hypothesis, extant depression literature reflects 
substantive parallels with the AD literature. Lopez-Leon and colleagues (2008) found that 
individuals who possessed an ApoE-2 allele, compared to the e3 allele, had a risk reduction of 
49% in developing MDD; this effect mimics the protective effect seen between ApoE-2 and AD. 
Studies have also demonstrated the detrimental effect of ApoE-4, whereby ApoE-4 carriers 
exhibited a significantly higher risk of increased depressive symptomatology in older adults, 
with odds ratios ranging from 1.75 to 6.1 (Rigaud et al., 2001; Skoog et al., 2015). With regard 
to the onset of depression in later-life, the mean age of onset for ApoE-4 carriers was 
significantly lower than that for non-carriers (51.4±20.7 years and 58.8±16.8 years, respectively; 
Butters et al., 2003). Although results suggesting a link between ApoE and depression are 
compelling, the literature also includes studies within which no effect was apparent. For 
example, in a study of over 17,500 individuals aged 41 to 80 (mean age 60.9 years), there was no 
difference in MDD prevalence across ApoE genotypes (Surtees et al., 2009). 
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CVB, Depression, and ApoE: A Potential Intersection 
 The strongly supported relationship between the CVB and the development of depression 
in later life (for review, see Scott & Paulson (Under Review)), in conjunction with the effect that 
ApoE genotype has on lipoprotein metabolism and cardiovascular disease, suggests an 
intersection of these three constructs. Research examining the relationship between CVB, ApoE, 
and depression has been sparse. Some studies have yielded ApoE carriage as a significant 
moderator of CVB’s positive predictive effects on depressive symptomatology in older adults 
(Lavretsky et al., 2000; Nebes et al., 2001). Not only have ApoE-4 carriers with comorbid CVB 
been shown to have greater depressive symptomatology, but they also may experience a greater 
number of depressive episodes and have a lower mean age of depression onset (mean age of 
onset for ApoE-4 carriers = 50.8 ± 18.7 years; Lavretsky et al., 2000). However, the findings by 
Lavretsky et al. (2000) and Nebes et al. (2001) were generated from small sample sizes (16 and 
92 participants, respectively), limiting the interpretation of their results. 
 Longitudinal relationships addressing the relationship between ApoE carriage, CVB, and 
later-life depression are relatively few among the literature. Support for the hypothesized model 
is dispersed across studies, though no single study has integrated variables into a single, coherent 
theoretical or empirical model with an adequately sized sample. An adequate evaluation of 
ApoE, CVB, and depressive symptomatology as it relates to aging requires a large sample of 
adults over the age of 65 and a longitudinal approach. The present study is the first of our 
knowledge to examine how ApoE carriage moderates the relationship between cerebrovascular 
health and depression longitudinally from mid-life to later-life.  
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Methods 
Participants 
The present study will utilize data collected through the Wisconsin Longitudinal Study (WLS). 
The WLS is a longitudinal cohort study that includes over 10,000 randomly selected 
representatives of the 1957 high school graduating class from Wisconsin. Participants were 
originally recruited in 1957 with an in-person questionnaire, then follow up data collections were 
gathered in 1964 (mail survey of parents), 1975 (telephone survey), 1993 (telephone and mail 
surveys), 2004 (telephone and mail surveys), and 2011 (in-person survey and mail survey; Herd 
et al., 2014). The WLS includes a wide breadth of information on its participants, including 
demographics, mental health status, medical health status, genetic variables, and measures of 
cognition. The initial goals of the WLS were to assess the demand for post-high school 
education, to determine if promising high school students were attending college or university, 
and what circumstances contributed to these education plans via a state-sponsored questionnaire 
(Little, 1958). Follow up studies were originally conducted to examine the extent to which 
family background and childhood experiences and aspirations affected educational and 
occupational attainment (Herd et al., 2014). Since 1991, the WLS has been principally funded by 
the National Institutes for Health and National Institute on Aging, with additional support 
provided by the Vilas Estate Trust, the National Science Foundation, the Spencer Foundation, 
and the Graduate School of the University of Wisconsin-Madison (Herd et al., 2014).  
 The data relevant to this study is found in the 1993, 2004, and 2011 waves. Participants 
who have missing data within the variables of interest were excluded from the study. 
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Measures 
Demographic Variables. Age, sex, and income were self-reported by the participant. 
Education was assessed as self-reported years of formal schooling.  
Cerebrovascular Health Variables. All medical variables used in this study were 
collected by self-report. Participants were asked “Has a doctor ever told you that you have . . .” 
high blood pressure or hypertension; high blood sugar; diabetes; heart attack, coronary heart 
disease, angina, congestive heart failure, or other heart problems; stroke. In this study, these 
comorbidities were grouped into three categories by organ system. Presence of hypertension was 
identified by endorsement of high blood pressure or hypertension. Presence of blood sugar 
dysregulation was identified by endorsement of high blood sugar or diabetes. Presence of cardiac 
disease was identified by endorsement of heart attack, coronary heart disease, angina, congestive 
heart failure, or other heart problems. Participants endorsing a history of stroke were excluded, 
as these individuals have been shown to be more likely to experience subsequent mood 
dysregulation (Bour et al., 2009). 
Total CVB. Total CVB is a continuous measure of cerebrovascular risk factors, 
comprising a participant’s scores on the hypertension, high blood sugar/diabetes, and heart 
disease measures and emitting a total score ranging from 0-3.  
Genetic Variable 
Apolipoprotein E. Saliva samples were collected from participants in 2006-2007 using 
Oragene kits and a mail-back protocol (Herd et al., 2014). An additional consent form was 
completed for usage of returned saliva samples. DNA genotyping was performed by 
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KBioscience in Hoddesdon, UK, using homogeneous fluorescent resonance energy transfer 
technology coupled to competitive allele-specific PCR (Roetker et al., 2012).  
Outcome Variable 
 Depression. Depression was measured using the Center for Epidemiological Studies 
Depression measure (CES-D; L.S. Radloff, 1977). The CES-D collapses ranges of scores (0, 1-2, 
3-4, and 5-7, then recodes these ranges to 0, 1, 2, or 3), for an individual’s total score ranging 
from 0-60. The internal consistency of the CES-D is high for older adults (coefficient alpha .85 
to .90), as is the validity of the measure (Lenore S. Radloff & Teri, 1986). Although the CES-D 
has a suggested cutoff score for probable depression, the present study will utilize this measure 
as a continuous degree of depressive symptomatology. 
Statistical Methods 
 A repeated-measures ANOVA (RM-ANOVA) was employed to evaluate the longitudinal 
effect that ApoE has on depressive symptomatology across three waves spanning mid-life (age 
53.20 years) to later-life (age 71.21 years). This analysis included an evaluation of the main 
effect of ApoE-conferred risk on depressive symptomatology, as well as the interaction between 
ApoE-conferred risk and time to assess the change in the expression of ApoE-carriage on 
depressive symptomatology as participants age. Further, this analysis included the interaction of 
ApoE-conferred risk and CVB to test moderation effects. Baseline sex, education, income, and 
marital status were set as control variables. This analysis was run using SPSS Version 22, and 
alpha level is .05 unless otherwise stated.  
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To model the effect that ApoE-conferred risk has on the relationship between CVB and 
depressive symptomatology over time while concurrently addressing methodological barriers in 
past work (i.e., listwise deletion), a moderated path model was employed (Figure 2.2). This 
model includes autoregressive pathways modeling to demonstrate, for example, the effect of 
CVB at time 1 on CVB at time 2. This model also includes cross-lagged pathways representing 
the hypothesized causal effect of CVB on depressive symptomatology over time. Interaction 
terms representing the effect that ApoE-conferred risk has on the relationship between CVB and 
depressive symptomatology in 2004 and in 2011 were included. Full information maximum 
likelihood estimation (FIML) was utilized to prevent listwise deletion and, in turn, to prevent the 
underrepresentation of at-risk respondents on variables associated with mortality-based attrition 
(e.g., those who are social marginalized which may affect one’s access to healthcare, or those 
carrying greater medical burden). Based on past work, sex, education, and income were set as 
control variables. Data was prepared in SPSS and the structural equation model analysis was 
performed utilizing Mplus software program (Muthen & Muthen, 2012). 
Results 
 The final sample consisted of 3,203 participants. Participant characteristics are provided 
in Table 1.2. Mean age of participants was 53 years in 1993, 64 years in 2004, and 71 years in 
2011. Within the moderated path model, the largest proportion of missing data was depressive 
symptomatology; 6.6%, 11.4%, and 17.2% of participants’ depressive symptomatology data was 
estimated using FIML in 1993, 2004, and 2011, respectively. Only 0.6% of participants’ CVB 
data was missing in 2011. Participants with incomplete data were listwise deleted in the RM-
ANOVA, resulting in a sample size of 2,350 participants. 
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Mauchly’s Test of sphericity for the RM-ANOVA was significant (W = .989, χ2(2, N=2350) = 
26.730,  p < .001), suggesting that the observed matrix does not have approximately equal 
variances and equal covariances; therefore, degrees of freedom were corrected using Huynh-
Feldt estimates of sphericity (ϵ = .999).  
With respect to tests of within-subjects effects, the effect of time on depressive 
symptomatology was not significant (F(1.998, 4648.855) = 1.613, n.s.), indicating that 
endorsement of depressive symptomatology was consistent across the period of the study. 
Within-subjects effects tests indicated a significant interaction between time and the sex of the 
participant (F(1.998, 4648.855) = 5.493, p = .004), suggesting a significant difference in 
depressive symptomatology between males and females across the period of the study. There 
was no significant interaction between time and CVB in 1993 on depressive symptomatology 
(F(1.998, 4648.855) = 0.259, n.s.), nor was there a significant interaction between time and 
ApoE-conferred risk on depressive symptomatology (F(1.998, 4648.855) = 1.569, n.s.), 
indicating no change in the effect that CVB or ApoE-conferred risk have on depressive 
symptomatology as participants age. With respect to tests of between-subjects effects that do not 
consider the effect of time, results indicated a significant main effect of education in 1993 (F(1, 
2327) = 5.253, p = .022), CVB in 1993 (F(1, 2327) = 16.274, p < .001), sex (F(1, 2327) = 4.787, 
p = .029), income in 1993 (F(4, 2327) = 4.476, p = .001), and marital status in 1993 (F(1, 2327) 
= 14.077, p < .001) on depressive symptomatology. There was no significant between-subjects 
effect of ApoE-conferred risk on depressive symptomatology (F(1, 2327) = 0.660, n.s.), 
suggesting that ApoE-conferred risk has no effect on depressive symptomatology. LSD post-hoc 
comparisons indicated that females endorsed significantly greater depressive symptomatology 
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compared to males (F(1, 2327) = 4.787, p = .029), that married participants endorsed 
significantly less depressive symptomatology compared to non-married participants (F(1, 2327) 
= 14.077, p < .001), and that participants with higher income endorsed significantly less 
depressive symptomatology compared to participants with lower income (F(4, 2327) = 4.476, p 
= .008). 
 The longitudinal effect that ApoE-conferred risk has on the relationship between CVB 
and depressive symptomatology over time was modeled by a moderated path analysis (Figure 
2.2). Overall, results suggest that the hypothesized model fit the data very well (RMSEA=0.041; 
Comparative Fit Index (CFI)=0.959, χ2(44, N=3203)=276.637, p<.00005). With respect to the 
model’s autoregressive pathways evaluating the relationship demonstrating how previous CVB 
affects future CVB, greater CVB in 1993 significantly predicted CVB in 2004 (β=0.498, 
SE=0.013, p<.001). Further, greater CVB in 2004 was significantly associated with greater CVB 
in 2011 (β=0.694, SE=0.009, p<.001). The autoregressive pathways demonstrating the 
relationship between prior and future depressive symptomatology revealed a similar relationship, 
whereby higher CES-D scores in 1993 were significantly associated with higher CES-D scores in 
2004 (β=0.548, SE=0.013, p<.001), and higher CES-D scores in 2004 were significantly related 
to higher CES-D scores in 2011 (β=0.594, SE=0.013, p<.001). With respect to the cross-lagged 
pathways identifying the relationship between CVB and depressive symptomatology from 
previous waves to future waves, greater CVB in 1993 was significantly associated with higher 
CES-D scores in 2004 (β=0.037, SE=0.016, p=.018). Greater CVB in 2004 was a marginally 
significant predictor of higher CES-D scores in 2011 (β=0.030, SE=0.016, p=.067). There was no 
significant main effect of ApoE-conferred risk on depressive symptomatology in 2004 or 2011. 
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 The interaction between ApoE-conferred risk and CVB was not significant with respect 
to depressive symptomatology in 2004 or 2011, indicating that ApoE does not moderate the 
relationship between CVB and future depressive symptomatology. Overall, the model accounted 
for 37.1% of the variance in depressive symptomatology in 2011. 
 In addition to the primary variables of interest, all control variables used in the model has 
statistically significant pathways dependent upon the wave. Specifically, level of education was 
significantly inversely related to the level of CVB in 1993 (β=-0.074, SE=0.019, p<.001), 2004 
(β=-0.074, SE=0.016, p<.001), and 2011 (β=-0.033, SE=0.013, p=.012). Level of education was 
also significantly inversely related to depressive symptomatology in 2004 (β=-0.036, SE=0.016, 
p=.027) and 2011 (β=-0.039, SE=0.016, p=.017). Participant income was significantly inversely 
associated with level of depressive symptomatology in 1993 (β=-0.127, SE=0.019, p<.001), 
2004 (β=-0.040, SE=0.017, p=.017), and 2011 (β=-0.043, SE=0.017, p=.012). Sex of the 
participant was significantly inversely associated with level of CVB in 1993 (β=-0.074, 
SE=0.018, p<.001), 2004 (β=-0.100, SE=0.016, p<.001) and 2011(β=-0.064, SE=0.013, p<.001), 
suggesting that male sex is associated with higher levels of CVB. Lastly, sex of the participant 
was significantly associated with depressive symptomatology in 1993 (β=0.095, SE=0.018, 
p<.001), and was marginally significantly associated with depressive symptomatology in 2004 
(β=0.030, SE=0.016, p=.061), suggesting female sex was associated with higher depressive 
symptomatology. 
Discussion 
 ApoE has inconsistently been identified as a genetic risk factor for vascular depression. 
The implication of ApoE carriage in various neurological diseases (e.g., AD, Wilson’s disease, 
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and Parkinson’s disease; Blacker et al., 1997; Farrer et al., 1997; Li et al., 2004; Liu et al., 2013; 
Schiefermeier et al., 2000) suggests a similar effect would exist for depression, given the 
neurobiological components of disordered mood. The present study is the first of our knowledge 
to evaluate the potential moderating effect of ApoE on the relationship between CVB and the 
development of depressive symptomatology, while concurrently addressing the methodological 
barriers identified in past work (e.g., small sample sizes, a sample younger than 65, and methods 
that underrepresent at-risk individuals with respect to characteristics related to mortality-based 
attrition, such as high depressive symptomatology, high CVB, and high levels of medical 
burden).  
 The findings of the present study suggest that ApoE-conferred risk is not implicated in 
the predisposition or perpetuation of depressive symptomatology, nor do they suggest ApoE as a 
moderator of the effect of CVB on depressive symptomatology. These results exemplify the 
intersection of two lines of research: (1) genetic risk factors for depression, and (2) genetic risk 
factors for CVB, both of which have examined the influence of ApoE carriage. Our null findings 
are consistent with extant research showing no significant association between ApoE and 
depression, CVB, or their combination (Cervilla et al., 2004; Surtees et al., 2009).  As 
importantly, these results contradict previous findings that ApoE-4 carriage is linked to increased 
risk for late-onset depression (Rigaud et al., 2001) as well as more severe depressive 
symptomatology and incident minor depression in elders who were non-depressed at baseline 5-
years prior (Skoog et al., 2015). 
 The current study was pursued in the justifiable belief that ApoE would relate to 
depressive symptomatology in the absence of methodological barriers common within the 
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literature. The aforementioned methods included a longitudinal design, a large, appropriately 
aged sample, and a solution to missing data to ensure that effects are not underrepresented due to 
listwise deletion of individuals with missing data on variables associated with mortality-based 
attrition. Our null results offer one potential explanation not of a methodological nature, but of 
reporting bias: there may be a distorted portrayal of the influence of ApoE on depressive 
symptomatology in the literature due to the difficulty associated with publishing null findings. It 
is impossible to determine whether past findings of a relationship between ApoE carriage and 
depressive symptomatology reflect type I error. Given that meta-analyses typically employ 
published research, the underrepresentation of null findings in publicized literature may lead to 
an undue overrepresented effect in these studies. Yet even with a potential misrepresentation of 
the influence of ApoE on depressive symptomatology in the literature, one meta-analysis still 
failed to find a significant effect of ApoE-4 on depression (Lopez-Leon et al., 2008).  
  The primary limitation of this study is the use of a racially homogeneous, well-educated 
sample. The effect of ApoE on various neurological diseases such as AD has been shown to 
fluctuate between ethnic groups (Tang et al., 1998). Future research should seek to replicate 
these findings in a sample of greater racial and socioeconomic diversity.  A second limitation of 
this analysis is the use of self-reported health data in measuring CVB. However, this approach is 
consistent with past research on clinically defined vascular depression, and subjective accounts 
of medical burden have yielded high concordance with objective measures (e.g., medical records 
and examinations; Bush et al., 1989; Psaty et al., 1995). A third limitation exists in the evaluation 
of chronological change that is imposed by using only three defined time points over an extended 
span of time (i.e., 18 years). To our knowledge, however, very few datasets exist that represent 
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such a large number of participants from midlife to later-life, limiting the feasibility of a more 
ideal analysis of these inter-relationships.  
  Future research should continue to examine the impact of ApoE on neurological 
disorders, in conjunction with identifying alternative genetic risk factors for disordered health. 
The imminent increase in the number of older adults over the next three decades makes the 
identification of idiographic risk factors for disorders more prevalent in later-life critical. A 
better understanding of the diatheses by which pathology develops will inherently lead to more 
effective individualized treatments and subsequent improved collaboration across healthcare 
providers.   
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Table 1.1. Description of Characteristics of Sample, n = 5175. 
 
  1993 2004 2011 
Variable  M (SD) M (SD) M (SD) 
Age 53.20 (0.62) 64.31 (0.68) 71.21 (0.93) 
Education (years) 13.86 (2.37) 13.88 (2.39) 13.88 (2.39) 
CES-D 11.70 (6.98) 10.19 (6.14) 10.99 (6.69) 
CVB (range 0 to 3) 0.26 (0.50) 0.71 (0.78) 1.05 (0.89) 
Household Income $56,000 ($50,800) $48,944 ($56,000) $33,260 ($35,930) 
    
   
Percentage of 
Sample 
Female 
  
54.2 
Married 
  
73.3 
White 
  
98.5 
Black 
  
0.1 
Other race or refused to answer   1.4 
*Household income represented by median and IQR. 
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Table 1.2. Description of Characteristics of Sample, n = 3203. 
 
  
  1993 2004 2011 
Variable  M (SD) M (SD) M (SD) 
Age 53.17 (0.61) 64.28 (0.66) 71.08 (0.86) 
Education (years) 13.97 (2.42) 13.99 (2.44) 13.99 (2.44) 
CES-D 11.61 (7.03) 10.05 (5.96) 10.78 (6.52) 
CVB (range 0 to 3) 0.25 (0.49) 0.69 (0.77) 1.03 (0.88) 
Household Income* $59,230 ($49,555) $53,144 ($55,440) $35,108 ($35,653) 
    
   
Percentage of 
Sample 
Female   53.5 
Married   75.7 
White   98.6 
Black   0.1 
Other race or refused to answer  1.3 
   
ApoE Carriage 
        e2/e2 
  
0.4 
     e2/e3 
  
12.6 
     e2/e4 
  
2.0 
     e3/e3 
  
60.0 
     e3/e4 
  
23.0 
     e4/e4 
  
2.0 
*Household income represented by median and IQR.   
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Figure 2.1. The relationship between CVB and depressive symptomatology from mid-life to 
later-life. 
 
CVB = cerebrovascular burden. 
D = depressive symptomatology. 
§ denotes a significant relationship between the control variable and depressive symptomatology. 
ɸ denotes a significant relationship between the control variable and CVB. 
denotes p<.05. 
   denotes a n.s. relationship. 
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Figure 2.2. The relationship between CVB and depressive symptomatology, and the moderating 
effect of ApoE on that relationship, from mid-life to later-life. 
CVB = cerebrovascular burden. 
D = depressive symptomatology. 
ApoE = apolipoprotein E-conferred risk. 
§ denotes a significant relationship between the control variable and depressive symptomatology. 
ɸ denotes a significant relationship between the control variable and CVB. 
              denotes p<.05. 
              denotes a n.s. relationship. 
              denotes marginal significance. 
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